A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: Safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells Meeting Abstract


Authors: Foy, S.; Jacoby, K.; Bota, D.; Hunter, T.; Schoenfeld, A.; Pan, Z.; Stawiski, E.; Ma, Y.; Lu, W.; Peng, S. M.; Wang, C.; Yuen, B.; Dalmas, O.; Heeringa, K.; Sennino, B.; Conroy, A.; Bethune, M.; Mende, I.; White, W.; Kukreja, M.; Gunturu, S.; Humphrey, E.; Hussaini, A.; An, D.; Quach, B.; Ng, A.; Lu, Y.; Smith, C.; Campbell, K.; Anaya, D.; Skrdlant, L.; Huang, E.; Mendoza, V.; Mathur, J.; Dengler, L.; Purandare, B.; Moot, R.; Yi, M.; Funke, R.; Sibley, A.; Stallings-Schmitt, T.; Oh, D.; Chmielowski, B.; Abedi, M.; Yuan, Y.; Sosman, J.; Lee, S.; Williams, C.; Kim, S.; Keefe, M.; Leon, M.; Kim, Y.; Reeves, J.; Goldman, W.; Baltimore, D.; Heath, J.; Franzusoff, A.; Ribas, A.; Rao, A.; Mandl, S.
Abstract Title: A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: Safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells
Meeting Title: 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022)
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 10
Issue: Suppl. 2
Meeting Dates: 2022 Nov 8-12
Meeting Location: Boston, MA
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2022-11-01
Start Page: A1536
Language: English
ACCESSION: WOS:000919423401581
DOI: 10.1136/jitc-2022-SITC2022.1478
PROVIDER: wos
Notes: Meeting Abstract: 1478 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work